Pfizer identifies Synexus’ South African clinical research sites as INSPIRE sites
First in Africa to meet the exacting standards required to join Pfizer’s worldwide network of INSPIRE sites
Three of Synexus’ South African dedicated clinical research centres – Stanza, Watermeyer and Nyeleti – have been identified by Pfizer as meeting the exacting standards that the company demands to join a worldwide network of INSPIRE sites, which must be both highly productive and effective.
INSPIRE, which stands for Investigator Networks, Site Partnerships and Infrastructure for Research Excellence, means that these sites have early access to Pfizer‘s portfolio data and advanced information regarding the clinical trials to be sponsored by Pfizer. They are also involved in publications in scientific journals, protocol design, advisory boards and the sharing of best practice across the INSPIRE network.
Synexus, which is the world's largest multinational company focused on the recruitment and running of clinical trials, already has an INSPIRE site in Wroclaw in Poland.
‘We are really delighted that we have been able to identify these sites and add them to our INSPIRE network,’ said Tebogo Sebata, Investigator Site Development and Support Lead, Pfizer Global. ‘We put in place the INSPIRE programme so that we can work with the best sites across the world. Centres that have real expertise in the science of clinical trials, the infrastructure support that is necessary, proven recruitment strategies and the in-depth knowledge can help us maximise our development programmes going forward.’
Dr Sanet Aspinall, Managing Director of Synexus South Africa, commented, ‘We have had to go through an exhaustive assessment programme that looked at our previous experience, expertise across a range of therapeutic areas, infrastructure and resources and effective recruitment strategies.
‘This is not only excellent for our company but for South Africa as it shows that it is a very good place in which to carry out clinical trials.’
